mountaineer: clinical relevance of genomic profiling for tucatinib trastuzumab treatment in mcrc
Published 9 months ago • 59 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
2:28
mountaineer: impact of genomic alterations on tucatinib plus trastuzumab activity in mcrc
-
1:11
32 month follow-up of mountaineer: tucatinib and trastuzumab in her2 mcrc
-
2:29
mountaineer: tucatinib plus trastuzumab for her2 metastatic colorectal cancer
-
1:14
updated analysis from mountaineer: tucatinib and trastuzumab for her2-positive mcrc
-
0:56
mountaineer results: trastuzumab and tucatinib for her2 mcrc
-
0:47
mountaineer-03: tucatinib plus trastuzumab plus folfox for first-line treatment of mcrc
-
1:23
tucatinib and trastuzumab in the treatment paradigm of her2-positive mcrc
-
4:46
mountaineer: tucatinib in combination with trastuzumab for her2-positive metastatic colorectal c...
-
2:23
mountaineer-02: tucatinib in previously treated her2 gastric cancer
-
17:40
mountaineer study lead to the tucatinib/trastuzumab fda approval - in discussion w/ dr. bekaii-saab
-
1:01
dr. bekaii-saab on safety profile of tucatinib/trastuzumab in her2 amplified mcrc
-
0:36
tucatinib & trastuzumab /- chemo or pembrolizumab in unresectable or metastatic her2 gi cancers
-
1:19
targeted therapies for patients with her2 colorectal cancer
-
0:24
genomic testing for colorectal cancer - dr. douglas riegert-johnson
-
1:42
dr. bekaii-saab on the rationale to explore tucatinib/trastuzumab in her2-overexpressing mcrc
-
1:12
challenges in implementing genomic testing for metastatic colorectal cancer
-
3:08
targeting less common mutations in colorectal cancer
-
1:04
dr. eckhardt on the role of regorafenib in colorectal cancer
-
15:52
debate: are novel targets such as her2 ready for prime time in colorectal cancer? - no